UPDATE: Investors Bullish On InterMune After Leerink Upgrade

In a report issued Monday, Leerink upgraded its rating of

from Market Perform to Outperform with a target price of $41. Howard Liang of Leerink anticipates that recent developments in trials done by InterMune should provide the company with plenty of upside. Esbriet particularly is one of the drugs that much of InterMune's success will hinge on, based on Liang's views. Investors have been extremely bullish on InterMune as it is surging in Monday's session up 14.5 percent to $39.30 at last check.